A webinar for primary care physicians was held

Employees of the Department of Internal Medicine №3 and Endocrinology joined the training and information event aimed at raising awareness of the peculiarities of the course and treatment of patients with endocrine pathology in the pandemic COVID-19.
The webinar was organized by the Department of Health of the Kharkiv Regional State Administration for Primary Care Physicians.
Professor, MD Zhuravlyova Larysa gave a lecture “Pandemic during the pandemic: diabetes and COVID-19”, Associate Professor, Ph.D. Moiseenko Tetyana  reported on the topic “Adrenal glands and COVID-19”, and Associate Professor of the department, Ph.D. Elhaj Olena  reported on “Diagnosis and management of patients with thyroid disease in COVID-19”.
Thanks to organizers and participants of the webinar for the opportunity to take part in this event!

The Festival of Youth Science took place

On January 24-26, 2022, the Festival of Youth Science took place within the framework of the Scientific Session of Kharkiv National Medical University. Students and young scientists of the Department of Internal Medicine №3 and Endocrinology took an active part in it and won prizes.

As part of the festival, January 24 , а brain-ring of students and young scientists “Medicine without Borders” took place, where the team of our department “People in White” took second place (supervisor Assoc. Prof. Lakhno OV).

On January 25, the interuniversity conference of young scientists and students “Medicine of the third millennium” took place. In the section “Internal Medicine” the second place was taken by Kuye Adesegun Jacobs and Azuvike Uchechi Blessing for the report “The effects of the COVID-19 pandemic on the total body weight and its associated symptoms” (supervisor Assoc. Prof. Elhazh OV).

Aayushi Tanvar’s speech “Modern methods of diagnosis and treatment of hemochromatosis” was awarded a diploma for the best presentation (supervisor Assoc. Prof. Fedorov VA).

On January 26, the final plenary session of the Scientific Session was held, which was opened by Professor LV Zhuravlyova with actual report “Pandemic during the pandemic: diabetes and COVD-19”.

Congratulations to the participants and their supervisors! We wish you inspiration and further scientific achievements.

The procedure for providing medical care at COVID-19 has been updated (from 06.04.2021)

Наказ МОЗ України від 06.04.2021 № 638 “Про внесення змін до протоколу «Надання медичної допомоги для лікування коронавірусної хвороби (COVID-19)»”

The annual student scientific conference «Topical Issues of Internal Medicine» was held


On December 22, at the Department of Internal Medicine No. 3 and Endocrinology, an annual student scientific conference «Topical Issues of Internal Medicine» was held. Читать дальше »

The procedure for providing medical care at COVID-19 has been updated

Наказ МОЗ України від 20.11.2020 № 2693 “Про внесення змін до протоколу «Надання медичної допомоги для лікування коронавірусної хвороби (COVID-19)»”

Clinical work at the department continues

Завідувачка кафедри професор Журавльова Лариса Володимирівна, а також співробітники кафедри, протягом усього періоду  карантину продовжують виконувати лікувально-консультативну роботу в КНП ХОР “Обласна клінічна лікарня”.

A public defense of the thesis took place in a distance format

On October 9, 2020, an on-line meeting of the specialized Academic Council D 64.600.04 took place, at which 2 dissertations were successfully defended. Professor Zhuravlyova Larysa Volodymyrivna spoke with the official opponent of Pavlovsky’s doctoral dissertation “Features of the course, diagnosis and treatment of patients with non-alcoholic fatty liver disease on the background of type 2 diabetes mellitus”.

Despite the pandemic and long quarantine restrictions, professional and scientific life continues!

Studying at the department during COVID-19 pandemic

On September 1, a new academic year began at the department for 4th year students, bachelors,  interns and graduate students. According to the order of the management of KhNMU, practical classes at the department are held in a mixed mode: in class, in compliance with all anti-epidemic measures, and distantly on the information and educational portal “Distance learning of KhNMU”.

At the entrance to the department, all participants of the educational process undergo temperature screening, antiseptic wetting of hands. Students in the department move in masks.

The head of the department, professor Zhuravlyova Larysa, checked the readiness of the distance courses of the discipline for the beginning of the educational process in accordance with the requirements. Also, information boards for students were updated with up-to-date information on the features of blended learning and the COVID-19 pandemic.

A virtual patient simulator BODY INTERACT has appeared in KhNMU

Читать дальше »

(Ukrainian) Клінічні рекомендації для дорослих пацієнтів із ревматичними захворюваннями в умовах пандемії COVID-19

Запропоновано адаптований переклад рекомендацій для хворих на ревматичні захворювання, представлений експертами Європейської
антиревматичної Ліги (EULAR) та Американського коледжу ревматологів (ACR) в зв’язку з проблемою COVID-19. Читать дальше »

(Ukrainian) ПОЗИЦІЯ ВСЕУКРАЇНСЬКОЇ АСОЦІАЦІЇ РЕВМАТОЛОГІВ ЩОДО ВИКОРИСТАННЯ ДЕФІЦИТНИХ РЕСУРСІВ ПІД ЧАС ПАНДЕМІЇ COVID-19 (адаптовано із позицій провідних асоціацій ревматологів — American Сollege of Rheumatology, Canadian Rheumatology Association)

Читать дальше »

Do prescribe ACE inhibitors and ARBs in patients with cardiac COVID-19?

The American Heart Association (AHA), American College of Cardiology (ACC) and the American Society of heart failure (HFSA) on March 17 released a new joint statement calling for continued use of antagonists of the renin-angiotensin-aldosterone system (RAAS) in patients, regardless of theoretical fear that their use may worsen the results if infection COVID-19.

Recently, a similar statement was made by the European Society of Cardiology (ESC), and the European Society of hypertension, the Canadian Society of cardiovascular disease and the International Society for hypertension.

Experts say that people with cardiovascular disease are exposed to much higher risk of serious complications, including death from COVID-19, however, a recent study – the actual data do not support the need for discontinuation of ACE inhibitors or angiotensin receptor blockers (ARBs), and researchers recommend that doctors take into account all the individual needs of each patient before making any changes in appointments ACE inhibitors or ARBs.

The new coronavirus SARS-CoV-2, which causes COVID-19 infects human cells by binding to receptors APF2 and some animal studies have shown that this mechanism increases the expression APF2 heart.

In the Lancet article assumes that patients with diabetes and hypertension increased regulation APF2 of ACE inhibitors and ARBs may increase the risk of severe and fatal COVID -19.

The authors suggested that these drugs may partially contribute to more severe and deadly COVID-19 observed in people with hypertension, diabetes and cardiovascular disease.

This article received wide coverage in the media and social networks in the UK, resulting in patients treated with their doctors, and in some cases stopped medication.

Overall, the researchers recommend that the RAAS antagonists destination for those patients who are currently appointed by the following drugs for indications such as heart failure, hypertension or coronary heart disease.

However, scientists note, if patients with cardiovascular disease diagnosed COVID-19 have made individual decisions on treatment according to the hemodynamic status of each patient and the clinical picture.

 To date, no evidence of harm or good. More research is needed.

There is also a theory that ACE inhibitors and ARBs may paradoxically be useful in koronavirusniy infection.

This is because APF2 converts angiotensin II to angiotensin 1-7 vazodylyatatornyy, thereby potentially providing a hypotensive effect in animal studies has been shown that both types of drugs reduce severe lung damage in some viral pneumonia.

However, there is currently no experimental or clinical data that demonstrate a positive or negative results in the background use of ACE inhibitors, ARBs, or other antagonists RAAS in COVID-19 or in patients with COVID-19 with cardiovascular disease history, treated such drugs.

American Heart Association does not recommend adding or deleting any treatment-related RAAS, other than those based on standard clinical practice.

Literary links are amended–patsijentam-z-covid-19.aspx





  • 2023 (8)
  • 2022 (40)
  • 2021 (25)
  • 2020 (51)
  • 2019 (62)
  • 2018 (45)
  • 2017 (38)
  • 2016 (69)
  • 2015 (40)
  • 2014 (37)
  • 2013 (5)
April 2023
« Mar    

Subscribe site news: